Rockville, MD – According to filings with the U.S. Securities and Exchange Commission, Immunomic Therapeutics is raising $60,000,000.00 in new funding. Sources indicate as part of senior management Chief Financial Officer, Eric Winzer played a key role in securing the recent investment and it will aid in aggressively expanding the company, as well as broaden and accelerate product development.

About Immunomic Therapeutics

Immunomic Therapeutics’ investigational UNITE platform is founded in a combination of complementary technologies and capabilities: ITI’s proprietary lysosomal targeting technology, optimal use of adjuvants, antigen selection and optimization, a breadth of delivery methods, and the ability to manufacture material at a large scale. Immunomic Therapeutics’ nucleic acid vaccines have the potential to utilize the body’s natural biochemistry to develop a broad immune response including antibody production, cytokine release and critical immunological memory. This approach could put UNITE at the crossroads of immunotherapies in a number of illnesses, including cancer, allergy and infectious diseases. ITI’s lysosomal targeting technology is currently being employed in a Phase II clinical trial as a cancer immunotherapy.

To learn more about Immunomic Therapeutics, visit http://www.immunomix.com/

Contact:
Eric Winzer, Chief Financial Officer
301-968-3501
ewinzer@immunomix.com
https://www.linkedin.com/in/eric-winzer-2bb84436/

SOURCE: http://www.intelligence360.io
Copyright (c) 2020 SI360 Inc. All rights reserved